Immunogenicity and protection from malaria infection in BK-SE36 vaccinated volunteers in Uganda is not influenced by HLA-DRB1 alleles.
Immunogenicity and protection from malaria infection in BK-SE36 vaccinated volunteers in Uganda is not influenced by HLA-DRB1 alleles.
复制标题
乌干达接种 BK-SE36 疫苗的志愿者的免疫原性和对疟疾感染的保护不受 HLA-DRB1 等位基因的影响。
DOI：
10.1016/j.parint.2016.06.012
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Horii T.
中科院分区：
文献类型：
--
作者：
Tougan T;Ito K;Palacpac NM;Egwang TG;Horii T.
SE 36抗原来源于恶性疟原虫丝氨酸重复序列抗原5（serine repeat antigen 5，SERA 5），是一种很有前途的血液期疟疾疫苗候选抗原。SE 36抗原命名为BK-SE 36，用羟基铝凝胶（AHG）配制，并在良好生产规范（GMP）约束下生产。在乌干达的一项Ib期临床试验和随访研究中，与对照组相比，疟疾症状的风险降低了72%。虽然前景看好，但6-20岁人群中对疫苗有反应的人数约为30%，其中大多数在年轻人群中。这与Ia期临床试验相反，在该试验中，日本疟疾初治成人对疫苗的应答率为100%。一个重要的考虑因素是宿主遗传因素的参与，这些因素可能影响对疫苗接种产生有效免疫应答的能力以及对疟疾感染的易感性。因此，我们采用基于序列的分型（SBT）技术分析了人类白细胞抗原（HLA）-DRB 11等位基因的多态性。本研究中，DRB 1等位基因不影响BK-SE 36抗体应答和疫苗接种者对临床疟疾的易感性。
SE36 antigen, derived from serine repeat antigen 5 (SERA5) of Plasmodium falciparum, is a promising blood stage malaria vaccine candidate. Designated as BK-SE36, the SE36 antigen was formulated with aluminum hydroxyl gel (AHG) and produced under Good Manufacturing Practice (GMP) constraints. In a Phase Ib clinical trial and follow-up study in Uganda, the risk for malaria symptoms was reduced by 72% compared with the control group. Although promising, the number of responders to the vaccine in 6–20 years-olds was approximately 30% with the majority in the younger cohort. This is in contrast to the phase Ia clinical trial where response to the vaccine was 100% in Japanese malaria naive adults.A consideration that can be of importance is the involvement of host genetic factors that may influence the ability to mount an effective immune response to vaccination as well as susceptibility to malaria infection. We, therefore, analyzed allelic polymorphism of human leukocyte antigen (HLA)-DRB1alleles using sequence-based typing (SBT). In this study,DRB1alleles did not influence antibody response to BK-SE36 and the vaccinees susceptibility to clinical malaria.